Auro Laboratories Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Sharat Deorah

Chief executive officer

₹3.8m

Total compensation

CEO salary percentage	100.0%
CEO tenure	35yrs
CEO ownership	22.4%
Management average tenure	no data
Board average tenure	9.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sharat Deorah's remuneration changed compared to Auro Laboratories's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹72m
Sep 30 2023	n/a	n/a	₹48m
Jun 30 2023	n/a	n/a	₹31m
Mar 31 2023	₹4m	₹4m	₹24m
Dec 31 2022	n/a	n/a	₹11m
Sep 30 2022	n/a	n/a	₹14m
Jun 30 2022	n/a	n/a	₹19m
Mar 31 2022	₹12m	₹12m	₹28m
Dec 31 2021	n/a	n/a	₹39m
Sep 30 2021	n/a	n/a	₹53m
Jun 30 2021	n/a	n/a	₹69m
Mar 31 2021	₹12m	₹12m	₹72m
Dec 31 2020	n/a	n/a	₹61m
Sep 30 2020	₹6m	₹6m	₹51m
Jun 30 2020	n/a	n/a	₹43m
Mar 31 2020	n/a	n/a	₹41m
Dec 31 2019	n/a	n/a	₹52m
Sep 30 2019	n/a	n/a	₹55m
Jun 30 2019	n/a	n/a	₹49m
Mar 31 2019	₹6m	₹6m	₹44m
Dec 31 2018	n/a	n/a	₹37m
Sep 30 2018	n/a	n/a	₹36m
Jun 30 2018	n/a	n/a	₹37m
Mar 31 2018	₹5m	₹5m	₹35m

Compensation vs Market: Sharat's total compensation ($USD44.98K) is about average for companies of similar size in the Indian market ($USD39.27K).

Compensation vs Earnings: Sharat's compensation has been consistent with company performance over the past year.

CEO

Sharat Deorah (73 yo)

35yrs

Tenure

₹3,750,000

Compensation

Mr. Sharat Sahadeolal Deorah, B.Com. serves as the Managing Director and Executive Chairman of the Board at Auro Laboratories Limited. He serves as Director since May 26, 1989 at Auro Laboratories Limited.

Board Members

Name	Position	Tenure	Compensation	Ownership
Sharat Deorah	Executive Chairman & MD	35yrs	₹3.75m	22.38% ₹ 353.4m
Siddhartha Deorah	Whole Time Director	24.8yrs	₹3.75m	7.15% ₹ 112.9m
Kiran Kulkarni	Additional Whole Time Director	3yrs	₹2.10m	0.00016% ₹ 2.5k
Kavita Sharma	Non-Executive Independent Director	9.2yrs	₹10.50k	no data
Vishal Jhunjhunwala	Non-Executive Independent Director	less than a year	no data	no data

9.2yrs

Average Tenure

52yo

Average Age

Experienced Board: 530233's board of directors are considered experienced (9.2 years average tenure).

Auro Laboratories Management

Management criteria checks 3/4

Key information

Recent management updates

Less than half of directors are independent

Auro Laboratories Limited Appoints Shaan Jain as Chief Financial Officer

Auro Laboratories Limited Announces the Resignation of Amit Mahipat Shah as Chief Financial Officer, Effective October 1, 2023

Auro Laboratories Limited Appoints Vishal Kailashchandra Jhunjhunwala as an Non-Executive & Independent Director

Less than half of directors are independent

Auro Laboratories Limited, Annual General Meeting, Sep 23, 2023

Recent updates

Investor sentiment improves as stock rises 26%

Less than half of directors are independent

Investor sentiment improves as stock rises 15%

Third quarter 2024 earnings released: EPS: ₹4.39 (vs ₹0.59 in 3Q 2023)

Auro Laboratories Limited to Report Q3, 2024 Results on Feb 06, 2024

Investor sentiment improves as stock rises 21%

Auro Laboratories Limited Appoints Shaan Jain as Chief Financial Officer

Investor sentiment improves as stock rises 23%

Second quarter 2024 earnings released: EPS: ₹3.16 (vs ₹0.34 in 2Q 2023)

Auro Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023

Auro Laboratories Limited Announces the Resignation of Amit Mahipat Shah as Chief Financial Officer, Effective October 1, 2023

Auro Laboratories Limited Appoints Vishal Kailashchandra Jhunjhunwala as an Non-Executive & Independent Director

Less than half of directors are independent

Auro Laboratories Limited, Annual General Meeting, Sep 23, 2023

Auro Laboratories Limited Announces Resignation of Govardhan Das Agarwal as Director

First quarter 2024 earnings released: EPS: ₹1.14 (vs ₹0.13 in 1Q 2023)

Auro Laboratories Limited to Report Q1, 2024 Results on Jul 31, 2023

Full year 2023 earnings released: EPS: ₹3.92 (vs ₹4.56 in FY 2022)

Investor sentiment improves as stock rises 23%

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: ₹0.59 (vs ₹0.98 in 3Q 2022)

Auro Laboratories Limited to Report Q3, 2023 Results on Feb 13, 2023

Second quarter 2023 earnings released: EPS: ₹0.34 (vs ₹1.14 in 2Q 2022)

Auro Laboratories Limited to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: EPS: ₹0.13 (vs ₹1.71 in 1Q 2022)

Auro Laboratories Limited to Report Q1, 2023 Results on Aug 02, 2022

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹11.52 in FY 2021)

Auro Laboratories Limited Announces Management Changes

Auro Laboratories Limited to Report Q4, 2022 Results on May 30, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Whole Time Director recently bought ₹86k worth of stock

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹1.71 (vs ₹2.22 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹11.52 (vs ₹6.51 in FY 2020)

Investor sentiment improved over the past week

Auro Laboratories Limited Appoints Mrs. Kavita Sharma as Independent Director

Auro Laboratories Limited to Report Q3, 2021 Results on Feb 11, 2021

Investor sentiment improved over the past week

New 90-day high: ₹98.80

Second quarter 2021 earnings released: EPS ₹3.62

Market bids up stock over the past week

Auro Laboratories Limited to Report Q2, 2020 Results on Nov 05, 2020

New 90-day high: ₹67.65

New 90-day high - ₹58.10

First quarter earnings released

Auro Laboratories Limited to Report Q1, 2021 Results on Aug 31, 2020

New 90-day high - ₹52.25

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age